The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [18F]FDG PET: Preliminary Results from a Prospective Cohort
Authors:
- Fabrizia GelardiFGFabrizia Gelardi
- Lara CavinatoLCLara Cavinato
- Rita De SanctisRSRita De Sanctis
- Gaia NinattiGNGaia Ninatti
- Paola TiberioPTPaola Tiberio
- Marcello RodariMRMarcello Rodari
- Alberto ZambelliAlberto Zambelli
- Armando SantoroArmando Santoro
- Bethania FernandesBFBethania Fernandes
- Arturo ChitiACArturo Chiti
- Lidija AntunovicLALidija Antunovic
- Martina SolliniMSMartina Sollini
Open Access
- 17 October 2024
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 14 (20) , 2312
Abstract
Background: Recently, radiomics has emerged as a possible image-derived biomarker, predominantly stemming from retrospective analyses. We aimed to prospectively assess the predictive role of [18F]FDG-PET radiomics in breast cancer (BC). Methods: Patients affected by stage I–III BC eligible for neoadjuvant chemotherapy (NAC) staged with [18F]FDG-PET/CT were prospectively enrolled. The pathological response to NAC was assessed on surgical specimens. From each primary breast lesion, we extracted radiomic PET features and their predictive role with respect to pCR was assessed. Uni- and multivariate statistics were used for inference; principal component analysis (PCA) was used for dimensionality reduction. Results: We analysed 93 patients (53 HER2+ and 40 triple-negative (TNBC)). pCR was achieved in 44/93 cases (24/53 HER2+ and 20/40 TNBC). Age, molecular subtype, Ki67 percent, and stage could not predict pCR in multivariate analysis. In univariate analysis, 10 radiomic indices resulted in p < 0.1. We found that 3/22 radiomic principal components were discriminative for pCR. Using a cross-validation approach, radiomic principal components failed to discriminate pCR groups but predicted the stage (mean accuracy = 0.79 ± 0.08). Conclusions: This study shows the potential of PET radiomics for staging purposes in BC; the possible role of radiomics in predicting the pCR response to NAC in BC needs to be further investigated.Keywords
Funding Information
- AIRC (2020-23596)
This publication has 32 references indexed in Scilit:
- Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indicationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2022
- Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasisBreast Cancer Research and Treatment, 2021
- Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)Breast Cancer Research and Treatment, 2020
- Clinical applications of breast cancer metabolomics using high-resolution magic angle spinning proton magnetic resonance spectroscopy (HRMAS 1H MRS): systematic scoping reviewMetabolomics, 2019
- A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patientsBreast Cancer Research and Treatment, 2018
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014